Using the PAH Biobank, we showed that 0.39% of the study patients (10/2572) had 12 TET2 mutations (75% predicted germline and 25% somatic), indicating that TET2 is a probable PAH gene [20]. This evidence concerns the gene TET2 and pulmonary arterial hypertension.